What is Zacks Research’s Estimate for WST Q4 Earnings?

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities researchers at Zacks Research raised their Q4 2025 earnings estimates for shares of West Pharmaceutical Services in a research report issued on Wednesday, April 9th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $1.86 for the quarter, up from their previous estimate of $1.85. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. The company had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%.

Other equities analysts also recently issued research reports about the company. KeyCorp decreased their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Citigroup assumed coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price target for the company. Evercore ISI assumed coverage on shares of West Pharmaceutical Services in a research note on Tuesday, March 18th. They set an “outperform” rating and a $275.00 price objective on the stock. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $332.50.

West Pharmaceutical Services Trading Up 3.4 %

WST opened at $210.75 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $394.42. The stock has a market cap of $15.24 billion, a PE ratio of 31.50, a PEG ratio of 6.74 and a beta of 1.22. The business has a 50 day moving average of $231.81 and a 200-day moving average of $289.73.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 annualized dividend and a dividend yield of 0.40%. West Pharmaceutical Services’s dividend payout ratio is presently 12.56%.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors have recently made changes to their positions in the company. Whipplewood Advisors LLC bought a new position in West Pharmaceutical Services in the 4th quarter valued at approximately $25,000. Retirement Wealth Solutions LLC purchased a new position in shares of West Pharmaceutical Services in the fourth quarter worth $34,000. Centricity Wealth Management LLC bought a new position in shares of West Pharmaceutical Services during the fourth quarter valued at $35,000. Cornerstone Planning Group LLC boosted its position in shares of West Pharmaceutical Services by 57.1% during the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 40 shares during the last quarter. Finally, IFP Advisors Inc increased its holdings in West Pharmaceutical Services by 150.9% in the 4th quarter. IFP Advisors Inc now owns 133 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.